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Background and methods: In order to characterize the expression pattern of SALL4, BMI-1 and ABCA3 genes in
patients with myeloid leukemia and those who achieved complete remission (CR) after chemotherapy. Real-time
PCR was used to determine the expression level of these genes in peripheral blood mononuclear cells from
24 patients with AML, eight patients with AML-CR, 13 patients with CML in the chronic phase (CML-CP), 12 patients
with CML in blast crisis (CML-BC), 13 patients with CML-CR and 11 healthy individuals (HI).
Results: Overexpression of the BMI-1 gene was found in the AML, CML-CP and CML-BC groups as compared
with HI group, while the BMI-1 expression level was lower in patients who achieved CR. In contrast, significantly
increased SALL4 expression was only found in AML group, additionally, SALL4 expression was lower in the CML-CP
and CML-CR groups compared with the HI group, while the SALL4 expression level in the CML-BC group was
higher and significantly greater than that in the CML-CP and CML-CR groups. Moreover, a positive correlation
between the expression of SALL4 and BMI-1 genes was found in samples from most groups. There was no
significant difference of ABCA3 expression level in AML and CML-BC group in comparison with HI group.
Interestingly, the ABCA3 expression level was significantly decreased in the CML-CP, AML-CR and CML-CR in
comparison with the HI group. Moreover, the ABCA3 expression level in all of the CR groups was lower than that
in their corresponding groups.
Conclusions: These results describe the altered SALL4, ABCA3 and BMI-1 expression pattern in different phases of
myeloid leukemia, which may relate to the development and progression to different diseases. SALL4 expression
was strongly correlated with BMI-1 in most of the myeloid leukemia patient groups, providing a potential link
between SALL4 and BMI-1 in leukemogenesis.
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The altered expression of genes, such as WT1, SCL, and
Notch1, that play crucial roles in the regulation of
hematopoietic progenitor cell proliferation is frequently
found in leukemia [1-7]. Increasing data show that the
genes involved in hematopoietic stem/progenitor cell
(HSPC) proliferation change their expression pattern
during leukemogenesis [8].
SALL4 (sal-like protein 4), a SALL gene family mem-
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reproduction in any medium, provided the orfactor, was originally cloned based on its sequence hom-
ology to Drosophila spalt (sal) [9-12]. Alternative spli-
cing generates two variant forms of human SALL4
mRNA, SALL4A and SALL4B, and each has a different
tissue distribution [9,13]. Recently, SALL4 has been
shown to play an important role in maintaining ES cell
(ESC) pluripotency and self-renewal properties. SALL4 is
involved in the self-renewal of leukemic initiation and
HSPC [14]. Moreover, recent data have shown that
SALL4 plays an essential role in myeloid leukemogenesis.
SALL4 is constitutively expressed in human leukemia
cell lines and primary acute myeloid leukemia (AML)
cells [9,13]. Transgenic mice that ubiquitously overexpress
SALL4B exhibit myelodysplastic syndrome (MDS)-like
symptoms and subsequently develop transplantable AMLd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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triggers apoptosis [15].
BMI-1 is a member of the polycomb group of proteins,
and it was initially identified in Drosophila as a repressor
of homeotic genes [9,16-18]. The BMI-1 gene was
initially isolated as an oncogene that cooperates with
c-myc in retroviral-induced B and T cell leukemia
[19,20]. In humans, BMI-1 is highly expressed in purified
HSCs, and its expression declines with differentiation
[9,21], and it plays an essential role in regulating adult,
self-renewing HSPC and leukemia stem cells [9,21-27].
Knockout of the BMI-1 gene in mice results in the pro-
gressive loss of all hematopoietic lineages [9,25]. BMI-1
expression appears to be important for the accumulation
of leukemic cells. Interestingly, inhibiting tumor stem
cell self renewal after BMI-1 deletion can prevent
leukemic recurrence. Recently, BMI-1 expression has been
used as an important marker for predicting MDS develop-
ment and the progression to AML [9,28]. BMI-1 overex-
pression was also observed in a significant number of
nasopharyngeal carcinoma tumors that correlated with
advanced tumor progression, invasive stage and poor
prognosis [19,29].
BMI-1 was recently demonstrated to be a direct SALL4
target gene. The induction of SALL4 expression is
associated with increased levels of histone H3–K4 and
H3–K79 methylation in the BMI-1 promoter, indicating a
novel connection between SALL4 and polycomb group
proteins in leukemogenesis and a mechanism whereby
aberrant SALL4 expression can directly alter BMI-1
expression [9].
Moreover, SALL4 expression was higher in drug resist-
ant primary acute myeloid leukemic patients than
those from drug-responsive cases. In addition, SALL4
expression was enriched in the SP when compared to
the non-SP counterpart. Recently, it is reported that
SALL4 could promote the expression of the ABC trans-
porter genes, such as ATP binding cassette transporter
A3 (ABCA3), suggesting that SALL4 can contribute
to the SP phenotype by regulating the expression of
ABCA3 and ABCG2 [15].
ABCA3 is a member of the ATP-binding cassette
(ABC) family of transport proteins and is required for
perinatal respiratory adaptation. Mutations in ABCA3
resulted in fatal neonatal lung disease [30,31]. ABCA3 is
highly expressed in AML and ALL patient samples and
its expression is associated with unfavorable clinical
treatment outcome. Furthermore, the expression of
ABCA3 is enriched in leukemic SP cells and has been
linked to multidrug resistance by facilitating lysosomal
sequestration of drugs in AML primary cells and cell
lines [15,32-35]. RNAi specific for ABCA3 led to a de-
crease of ABCA3 expression in T-ALL cell line such as
CCRF-CEM and Jurkat cells. Consequently, a significantsensitization of cells to cytostatic drugs was achieved
[35]. Moreover, both pharmacological blockade and the
silencing of ABCA3 enhanced susceptibility of target B-
cell lymphoma cells to anti-CD20 antibody-mediated
lysis. Mechanisms of cancer cell resistance to drugs and
antibodies are linked in an ABCA3-dependent pathway
of exosome secretion [36].
Little is known about the expression pattern of the
SALL4, ABCA3 and BMI-1 genes in patients with mye-
loid leukemia and patients that achieved complete remis-
sion after chemotherapy. In this study, we determined
the expression characteristics of the SALL4, ABCA3 and
BMI-1 genes in de novo AML and CML and complete
remission samples.
Results
The high amplification efficiency of the BMI-1 and
SALL4 genes was consistent with that of the β2M refer-
ence gene. The PCR products from all of the genes of
interest were confirmed using 2.5% agarose gel electro-
phoresis followed by sequencing (data not shown). The
BMI-1 and SALL4 genes were detected in all of the
PBMC samples from the healthy individuals and those
with myeloid leukemia.
Higher expression of BMI-1 in AML and CML
BMI-1 overexpression was found in the de novo AML
(median: 0.303, p <0.001), CML-CP (median: 0.295,
p=0.006), and CML-BC (median: 0.109, p=0.01) groups
in comparison with the HI group (median: 0.027); the
BMI-1 expression level in the AML-CR group (median:
0.078) was not significantly different compared with the
HI group (p=0.322). Interestingly, the BMI-1 expression
level in the CML-CR group (median: 0.003) was signifi-
cantly lower than that in the HI (p< 0.0001) and CML
groups (p< 0.0001).
We next analyzed BMI-1 expression in different AML
subtypes, including M2 (median: 0.400), M3 (median:
0.156) and M5 (median: 0.295), and all had a signifi-
cantly higher expression level compared to the HI group
(p=0.003, p=0.01 and p=0.004, respectively), while the
BMI-1 expression level in the M2-CR (median: 0.070)
and M3-CR (median: 0.099) groups was not significantly
different in comparison to that of the HI group (p=0.514
and p=0.361, respectively) (Figures 1 and 2).
Different expression pattern of SALL4 in AML and CML
The expression pattern appeared different for SALL4 in
the different myeloid leukemia in comparison with the
HI group (median: 0.394). While the SALL4 expression
level was increased in the AML group (median: 1.051;
p=0.009), CML-BC group (median: 1.563; p=0.016) and
the different AML subtypes M2 (median: 0.974;
p=0.039), M3 (median: 0.799; p=0.083) and M5 (median:
Figure 1 The BMI-1 (A), SALL4 (B) and ABCA3 (C) expression levels in the different myeloid leukemia groups and healthy individuals.
Shen et al. Cancer Cell International 2012, 12:42 Page 3 of 9
http://www.cancerci.com/content/12/1/421.465; p=0.026), it was lower in the AML-CR (median:
0.026; p=0.026), M2-CR (median: 0.105; p=0.151) and
M3-CR (median: 0.023; p=0.037) groups. Interestingly,
the level of SALL4 expression in the CML-CP (median:
0.093; p=0.213) and CML-CR groups (median: 0.025;p<0.0001) was lower in comparison with the HI group,
and the increased SALL4 expression level in the CML-BC
group (median: 1.563) was significantly higher than that in
the CML-CP (p=0.001) and CML-CR (p<0.0001) groups.


































































Figure 2 The BMI-1 (A), SALL4 (B) and ABCA3 (C) expression levels in the different AML subtypes and healthy individuals.
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AML-CR (p< 0.0001), M2 vs. M2-CR (p=0.017), M3 vs.
M3-CR (p=0.007) and CML vs. CML-CR (p=0.011)
(Figures 1 and 2).
Low expression of ABCA3 in myeloid leukemia
The expression level of ABCA3 seemed low in the differ-
ent myeloid leukemia in comparison with the HI group.There was no significant difference of ABCA3 expres-
sion level in AML (median: 0.211; p=0.136), CML-BC
(median: 0.174; p=0.097) and the different AML sub-
types M2 (median: 0.242; p=0.215), M3 (median: 0.195;
p = 0.186) and M5 (median: 0.221; p=0.364) in compari-
son with the HI group (median: 0.313). While the
ABCA3 expression level was significantly decreased in
the CML-CP (median: 0.025; p <0.0001), AML-CR
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p <0.0001) in comparison with the HI group. Moreover,
the ABCA3 expression level in all of the CR groups
was lower than that in their corresponding groups i.e.,
AML vs. AML-CR (p=0.042) (Figures 1 and 2).Correlation of relative expression of BMI-1, SALL4 and
ABCA3 in myeloid leukemia
Correlation analysis of the relative expression levels of
BMI-1 and SALL4,SALL4 and ABCA3 was performed
using Spearman’s rank correlation analysis of the HI,
AML and CML groups. A positive expression correl-
ation level for BMI-1 and SALL4 genes was found in the
HI (rs=0.687, p=0.014), AML (rs=0.762, p< 0.0001), M3
(rs=0.994, p< 0.0001), CML-CP (rs=0.742, p=0.004),
CML-BC (rs=1=0.846, p=0.001), M2-CR (rs=1, p < 0.0001)
and CML-CR (rs=0.534, p=0.049) groups. However,




















































Figure 3 Correlation analysis of the relative BMI-1 and SALL4 express
CML-CR (E) and CML-BC (F) groups. The data of M2, M3, M3-CR, M2-CR,the M2 (rs=0.381, p=0.352), M5 (rs=0.643, p=0.086),
M3-CR (rs=0.40, p= 0.060) and AML-CR (rs=0.643,
p=0.086) groups (Figure 3). A similar result with a
positive expression correlation level for genes SALL4
and ABCA3 was found in the HI (rs=0.783, p=0.004),
while there was no significant correlation between the
expression levels of both genes in all myeloid leukemia
groups (Figure 4).Discussion
BMI-1 and SALL4 are stem cell genes that modulate
stem cell pluripotency and play a role in leukemogenesis.
Dysregulated expression of both genes may have a
cooperative effect in leukemogenesis [37]. Patients with
RA and RARS who have a higher percentage of BMI-1+
cells showed disease progression to RAEB, suggesting
that BMI-1 is a novel molecular marker that predicts the




















































ion levels in healthy individuals (A), AML (B), AML-CR (C), CML (D),




































































Figure 4 Correlation analysis of the relative SALL4 and ABCA3 expression levels in healthy individuals (A), AML (B), CML (C) and the
CML-BC (D) groups.
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AML and CML at diagnosis and those in complete
remission.
It has been shown that BMI-1 overexpression occurs
in a variety of cancers including several types of leuke-
mias and lymphomas [38]. In this study, BMI-1 was
found to be overexpressed in AML and chronic phase
CML patient groups; and its expression level was lower
in patients who achieved complete remission. Similar
results were reported by Sawa, M et al. who found that
moderate to high BMI-1 expression was detected in
AML patients, and the AML-M0 subtype showed higher
relative expression of the BMI-1 transcript [39]. In
addition, Merkerova, M et al. demonstrated that BMI-1
and its significantly higher BMI-1 transcript level in
CML cells seem to play a secondary role in CML
transformation [40]. Our results also indicate that a
decreased BMI-1 expression level is associated with
complete disease remission. Interestingly, the BMI-1
expression level in the CML-BC group appeared to
be low in comparison with the de novo CML group,
although the difference was not significant. Further
investigation is needed using a larger patient cohort
to extend our findings. Preliminary results indicate
that BMI-1 may have potential as a therapeutic target for
myeloid leukemia. It has been reported that BMI-1 deple-
tion by RNA interference leads to reduced U937 cell
growth and proliferation and increased apoptosis [41],and an antisense BMI-1 gene can inhibit the growth
of K562 cells and upregulate p16 expression in K562
cells [42].
Using immunohistochemistry and real-time PCR,
SALL4 was demonstrated to be constitutively expressed
in human primary acute myeloid leukemia [13]. In this
study, we found that SALL4 was overexpressed in differ-
ent primary AML subtypes, and its expression was lower
in the AML-CR patient group. These results are similar
to the findings of Jeong, HW et al. who showed that
AML patients who responded to treatment had decreas-
ing SALL4 expression throughout the course of treat-
ment, while AML patients with disease relapse or drug
resistance had increasing SALL4 expression, which was
correlated with disease progression [15]. Interestingly,
unlike the SALL4 expression characteristics in AML, the
SALL4 expression level in the CML-CP and CML-CR
groups was lower. Moreover, the SALL4 expression level
in patients with chronic phase CML was significantly
lower than that in the CML-CR group. There is no dir-
ect evidence demonstrating the SALL4 expression level
in CML-CP and comparing the expression feature to
healthy individuals; however, Lu and colleagues have
found that the SALL4 protein was overexpressed in
CML samples in blast crisis but not those in chronic
phase by FACS [37]. Our results also demonstrated that
SALL4 expression was higher in the CML-BC group in
comparison with the CML-CP and CML-CR groups;
Table 1 The details of samples used in study
Diagnosis Subtype Numbers Age (year)
Total Male Female Range Median
AML 24 12 12 6-69 32
M2 8 4 4 16-61 42.5
M3 8 3 5 24-52 30
M5 8 6 2 6-69 30.5
AML-CR 8 4 4 16-61 32
M2-CR 4 3 1 39-61 47
M3-CR 4 1 3 16-25 20
CML-CP 13 11 2 13-64 38
CML-BP 12 6 6 23-66 42.5
CML-CR 13 7 6 15-55 32
HI 11 5 6 24-57 36
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son with the HI group. Is it possible that SALL4 is pre-
ferentially expressed in leukemic blasts? These results
are similar to a report by Cui W et al. who demonstrated
that only precursor B-cell lymphoblastic leukemias/
lymphomas and AML had detectable SALL4 in neoplas-
tic tissues [43]. The different SALL4 expression patterns
in AML and CML suggest that these two disease entities
may have different biological characteristics and/or
mechanisms of leukemogenesis, at least for the associ-
ation between SALL4 and pathogenesis. However, there
are not reports comparing the data of SALL4 expression
level in CML-CP to healthy individuals, it is difficult
to evaluate the significance of this finding. Recently,
research from Zhu et al. showed that hematopoietic
transcription factor PU.1 expression was significantly
lower in newly diagnosed APL patient samples as com-
pared to normal hematopoietic cells, which may relate
to the expression level of PML-RARα, and they found
that suppression of PU.1 expression occurred concur-
rently with PML-RARα expression, the authors sug-
gested that low PU.1 expression in APL patients is
required for disease initiation and progression [44]. This
finding might provide a direction in farther analysis the
correlation of SALL4 with BCR-ABL in the pathogenesis
of CML and to address this question.
In principle, the BMI-1 and SALL4 gene expression
level should be positively correlated in stem cells [9].
Little is known about the expression pattern and differ-
ences in the SALL4 and BMI-1 genes in patients with
AML and CML. In this study, we analyzed the correl-
ation between the relative expression levels of BMI-1
and SALL4. A positive expression level correlation was
found for both genes in HI, AML, chronic phase CML,
CML-BC and CML-CR patient groups; however, there
was no significant correlation between these genes in
patients with AML-CR, leaving their role in this group
an open question. These results indicate that a positively
correlated expression pattern is a common feature in
patients with myeloid leukemia and healthy individuals,
and both genes may cooperate during cell proliferation
and differentiation.
Based on the different expression features of SALL4 in
AML and CML, we further analyzed its regulating gene
ABCA3, which is a member of the ATP-binding cassette
(ABC) family of transport proteins [30,31]. Unlike the
description by Wult, Norwood and Steinbach groups,
who showed that ABCA3 is highly expressed in acute
meyloid leukemia samples and is associated with
unfavorable clinical treatment outcome [24,33,45], in the
present study, lower expression level of ABCA3 was
found not only in AML but also in CML groups, espe-
cially in CML-CP and CR groups. Moreover, the expres-
sion level of ABCA3 lost the correlation with SALL4expression in leukemia patients. To determine whether
these results relate to favorable clinical outcome, fur-
ther investigation is needed. Additionally, detection of
ABCA2, ABCB2 and ABCC10, which were found over-
expressed in childhood AML, may be worthy to build
the gene regulation network in proliferation of myeloid
leukemia cells.
In conclusion, we determined the expression charac-
teristics of the SALL4, ABCA3 and BMI-1 genes in dif-
ferent phases of AML and CML. Further studies will be
needed to determine whether BMI-1 and SALL4 are
novel therapeutic targets for leukemic stem/initiation
cells in primary myeloid leukemia.
Methods
Samples
Twenty-four newly diagnosed and untreated patients
with AML, eight cases with AML in complete remission
(AML-CR), thirteen newly diagnosed and untreated
patients with CML in chronic phase, 13 cases with
CML-CR, and 12 cases with CML in blast crisis (CML-
BC),were recruited, the details of the samples was listed
in Table 1. The diagnoses of all patients were based on
cytomorphology, immunohistochemistry, and cytoimmu-
nological and cytogenetic analysis. Peripheral blood
mononuclear cells (PBMCs) from 11 healthy individuals
(HI) served as controls. Peripheral blood was collected
by heparin anticoagulation, and PBMCs were separ-
ated using the Ficoll-Hypaque gradient centrifugation
method. All procedures were conducted in accordance
with the guidelines of the Medical Ethics committees of
the health bureau of Guangdong Province, China.
RNA extraction and cDNA synthesis
RNA was extracted using the Trizol kit (Invitrogen,
Carlsbad, CA, USA) and then reverse-transcribed into
first-strand cDNA using random hexamer primers and
Table 2 Primer sequences used for real-time PCR
Primer Sequence Accession No PCR product size
SALL4-f 5’-TGCAGCAGTTGGTGGAGAAC-3’ NM_020436.3 68 bp
SALL4-r 5’-TCGGTGGCAAATGAGACATTC-3’
BMI-1-f 5’-TAAGCATTGGGCCATAGT-3’ NM_005180.8 140 bp
BMI-1-r 5’-ATTCTTTCCGTTGGTTGA-3’
ABCA3-f 5’-CTCCGAGAAGGACTTTGAGG-3’ NM_001089.2 144 bp
ABCA3-r 5’-TCCGTGTGTAACTGAACCGT-3’
β2M-f 5’-TACACTGAATTCACCCCCAC-3’ J00105 144 bp
β2M-r 5’-CATCCAATCCAAATGCGGCA-3’
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according to the manufacturer’s instructions.Real-time quantitative reverse transcription–polymerase
chain reaction (qRT–PCR)
The expression levels of BMI-1, SALL4, ABCA3 and the
β2-microglobulin (β2-MG) reference gene were deter-
mined by SYBR Green I real-time PCR. Briefly, PCR was
performed in a 25 μL total volume containing 1 μL
of cDNA, 9 μL of 2.5× SYBR Green mix (Tiangen,
Beijing, China), and 10 μmol/L primer pairs. After initial
denaturation at 95°C for 2 min, 45 cycles consisting of
the following procedure were performed using an MJ
Research DNA Engine Opticon 2 PCR cycler (BIO-RAD,
USA): 15 s at 95°C, 40 s at 64°C for β2M and BMI-1, 60°
C for SALL4, and 63°C for ABCA3. The relative amounts
of the genes of interest and the β2-MG reference gene
were measured in two independent assays. The data are
presented as the relative expression of the genes of inter-
est relative to the internal control gene as determined by
the 2(−ΔΔCT) method [1-3,5,46]. Additionally, the specific
amplification of the PCR products was analyzed by melt-
ing curve analysis and agarose gel electrophoresis. The
primers used for real-time PCR for all gene amplifica-
tions were synthesized by Shanghai Biological Engineer-
ing Technology Services Co., Ltd. (Table 2). RT–PCR,
for the BMI-1, SALL4 and ABCA3 genes, was performed
using the same primers described above, and the PCR
products were sent to Shanghai Invitrogen Biotechnol-
ogy Co. for DNA sequence analysis.Statistical analyses
Differences in mRNA expression between two groups
were analyzed using the Mann–Whitney U test. Data are
presented as median. Spearman’s rank correlation ana-
lysis was used to analyze the SALL4, BMI-1 and ABCA3
mRNA levels in different samples using the SPSS 11.5
statistical software. Differences were considered statisti-
cally significant at P < 0.05.Competing interests
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